HLA NGS Typing and HLA/HPA/HNA Antibody Reagents

Summary

The tender covers the supply of reagents, consumables, controls and related laboratory equipment for three lots: high-resolution HLA typing by NGS sequencing, anti-HLA-I and anti-HPA antibody testing by Luminex, and anti-HLA-I/II and anti-HNA antibody testing by Luminex. The initial contract runs from 1 January 2027 to 31 December 2029, with a possible two-year extension. The estimated value is EUR 415,200 excluding VAT for the initial period and EUR 692,000 including the extension; the total budget including VAT for the initial period is EUR 502,392. The supplier must provide validated, CE-IVD/IVDR-compliant reagents, the required equipment, software, installation, qualification, maintenance, training and technical support. Estimated annual volumes are 576 HLA NGS determinations for Lot 1, 48 anti-HLA-I/anti-HPA determinations for Lot 2 and 100 anti-HLA-I/II/anti-HNA determinations for Lot 3. Offers are evaluated using technical quality criteria and price. A valid electronic certificate is required for electronic submission.